002019 亿帆医药
已收盘 06-17 15:00:00
资讯
新帖
简况
细胞免疫治疗概念盘中跳水，亿帆医药跌0.46%
自选股智能写手 · 06-13
细胞免疫治疗概念盘中跳水，亿帆医药跌0.46%
亿帆医药(002019.SZ)：间苯三酚注射液获药品注册证书
智通财经网 · 06-03
亿帆医药(002019.SZ)：间苯三酚注射液获药品注册证书
亿帆医药最新公告：子公司获得间苯三酚注射液药品注册证书
证券之星 · 06-03
亿帆医药最新公告：子公司获得间苯三酚注射液药品注册证书
亿帆医药(002019.SZ)：维生素K1注射液境内生产药品注册上市许可获受理
智通财经网 · 05-31
亿帆医药(002019.SZ)：维生素K1注射液境内生产药品注册上市许可获受理
亿帆医药最新公告：全资子公司收到维生素K1注射液药品注册受理通知书
证券之星 · 05-31
亿帆医药最新公告：全资子公司收到维生素K1注射液药品注册受理通知书
亿帆医药：感谢您的关注与提问。产品业绩我们将会根据信息披露规则进行披露，也请您理解
证券之星 · 05-31
亿帆医药：感谢您的关注与提问。产品业绩我们将会根据信息披露规则进行披露，也请您理解
亿帆医药最新公告：银杏叶丸获得新加坡注册批文
证券之星 · 05-13
亿帆医药最新公告：银杏叶丸获得新加坡注册批文
亿帆医药(002019.SZ)：银杏叶丸获新加坡注册批文
智通财经 · 05-13
亿帆医药(002019.SZ)：银杏叶丸获新加坡注册批文
亿帆医药获首创证券增持评级，自有制剂、创新药进入放量周期，业绩反转趋势明确
金融界 · 05-07
亿帆医药获首创证券增持评级，自有制剂、创新药进入放量周期，业绩反转趋势明确
上海证券：给予亿帆医药买入评级
证券之星 · 05-05
上海证券：给予亿帆医药买入评级
亿帆医药：感谢您的关注与提问。公司力争达到试生产条件同时预祝您五一劳动节快乐！
证券之星 · 04-30
亿帆医药：感谢您的关注与提问。公司力争达到试生产条件同时预祝您五一劳动节快乐！
天风证券：给予亿帆医药买入评级
证券之星 · 04-30
天风证券：给予亿帆医药买入评级
华安证券：给予亿帆医药买入评级
证券之星 · 04-29
华安证券：给予亿帆医药买入评级
亿帆医药（002019）2024年一季报简析：营收净利润同比双双增长
证券之星 · 04-25
亿帆医药（002019）2024年一季报简析：营收净利润同比双双增长
亿帆医药(002019.SZ)发一季度业绩，净利润1.46亿元，同比增长125.55%
智通财经 · 04-23
亿帆医药(002019.SZ)发一季度业绩，净利润1.46亿元，同比增长125.55%
4月23日亿帆医药涨5.81%，中银中国LOF基金重仓该股
证券之星 · 04-23
4月23日亿帆医药涨5.81%，中银中国LOF基金重仓该股
亿帆医药涨5.81%，华安证券二日前给出“买入”评级
证券之星 · 04-23
亿帆医药涨5.81%，华安证券二日前给出“买入”评级
亿帆医药(002019.SZ)控股子公司在研产品获欧盟委员会批准上市
智通财经网 · 03-24
亿帆医药(002019.SZ)控股子公司在研产品获欧盟委员会批准上市
亿帆医药(002019.SZ)：麻芩消咳颗粒获得新加坡注册批文
智通财经网 · 02-29
亿帆医药(002019.SZ)：麻芩消咳颗粒获得新加坡注册批文
亿帆医药(002019.SZ)部分董事、高管等完成增持301.34万股
智通财经网 · 02-18
亿帆医药(002019.SZ)部分董事、高管等完成增持301.34万股
暂无数据
公司概况
公司名称：
亿帆医药股份有限公司
所属行业：
医药制造业
上市日期：
2004-07-13
主营业务：
亿帆医药股份有限公司主要从事医药产品、原料药和高分子材料的研发、生产、销售及药品推广服务。主导产品为中成药、化药、生物药、维生素B5、维生素原B5等。
发行价格：
12.57
{"stockData":{"symbol":"002019","market":"SZ","secType":"STK","nameCN":"亿帆医药","latestPrice":12.96,"timestamp":1718607834000,"preClose":13,"halted":0,"volume":5721194,"delay":0,"floatShares":851000000,"shares":1226000000,"eps":-0.3832,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.04,"latestTime":"06-17 15:00:00","open":12.93,"high":13.05,"low":12.89,"amount":74216800,"amplitude":0.0123,"askPrice":12.97,"askSize":196,"bidPrice":12.96,"bidSize":7,"shortable":0,"etf":0,"ttmEps":-0.3832,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1718674200000},"adr":0,"adjPreClose":13,"symbolType":"stock","openAndCloseTimeList":[[1718587800000,1718595000000],[1718600400000,1718607600000]],"highLimit":14.3,"lowLimit":11.7,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1226024827,"pbRate":1.9,"roa":"--","roe":"1.72%","epsLYR":-0.45,"committee":-0.757641,"marketValue":15889000000,"floatMarketCap":11030000000,"peRate":-33.82046,"changeRate":-0.0031,"turnoverRate":0.0067,"status":1},"requestUrl":"/m/hq/s/002019/tweets","defaultTab":"tweets","newsList":[{"id":"2443432435","title":"细胞免疫治疗概念盘中跳水，亿帆医药跌0.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2443432435","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443432435?lang=zh_cn&edition=full","pubTime":"2024-06-13 09:43","pubTimestamp":1718243003,"startTime":"0","endTime":"0","summary":"06月13日，细胞免疫治疗概念盘中跳水，截至09点43分，细胞免疫治疗概念整体指数下跌0.50%，报689.710点。从个股上来看，该概念的成分股中，亿帆医药跌0.46%，华海药业、普蕊斯、百普赛斯跌幅居前。从资金上来看，截止发稿，细胞免疫治疗概念主力净流入为-2.36亿，其中华海药业受到资金热捧，主力净流入157.48万；拉长时间线来看，该板块近20日主力资金净流入-52.60亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240613094323af8d4d21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240613094323af8d4d21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["002019","BK0070","BK0201","BK0239","BK0028","BK0077","600521","BK0191","BK0012","BK0197","BK0185","BK0188"],"gpt_icon":0},{"id":"2440466038","title":"亿帆医药(002019.SZ)：间苯三酚注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2440466038","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440466038?lang=zh_cn&edition=full","pubTime":"2024-06-03 19:06","pubTimestamp":1717412775,"startTime":"0","endTime":"0","summary":"亿帆医药(002019.SZ)发布公告，公司全资子公司合肥亿帆生物制药有限公司于2...","market":"us","thumbnail":"https://img.zhitongcaijing.com/astock/14.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/14.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1130250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","BK0185","002019","BK0191","BK0070","BK0077","BK0197"],"gpt_icon":0},{"id":"2440463250","title":"亿帆医药最新公告：子公司获得间苯三酚注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2440463250","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440463250?lang=zh_cn&edition=full","pubTime":"2024-06-03 18:29","pubTimestamp":1717410582,"startTime":"0","endTime":"0","summary":"亿帆医药公告，全资子公司合肥亿帆生物制药有限公司于2024年6月3日收到国家药品监督管理局核准签发的间苯三酚注射液《药品注册证书》。间苯三酚注射液适用于治疗消化道和胆道功能障碍引起的急性痉挛性疼痛等。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060300023606.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0185","002019","BK0191","BK0070","BK0077","BK0197"],"gpt_icon":0},{"id":"2439960508","title":"亿帆医药(002019.SZ)：维生素K1注射液境内生产药品注册上市许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2439960508","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439960508?lang=zh_cn&edition=full","pubTime":"2024-05-31 19:34","pubTimestamp":1717155282,"startTime":"0","endTime":"0","summary":"亿帆医药(002019.SZ)发布公告，公司全资子公司合肥亿帆生物制药有限公司于2...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/astock/25.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/25.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1129284.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0070","BK0185","BK0077","BK0197","BK0239","BK0191","002019"],"gpt_icon":0},{"id":"2439912967","title":"亿帆医药最新公告：全资子公司收到维生素K1注射液药品注册受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2439912967","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439912967?lang=zh_cn&edition=full","pubTime":"2024-05-31 19:19","pubTimestamp":1717154379,"startTime":"0","endTime":"0","summary":"亿帆医药公告，全资子公司合肥亿帆生物制药有限公司于2024年5月30日收到国家药品监督管理局签发的维生素K1注射液境内生产药品注册上市许可《受理通知书》。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024053100040149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","BK0185","002019","BK0191","BK0197","BK0077"],"gpt_icon":0},{"id":"2439096268","title":"亿帆医药：感谢您的关注与提问。产品业绩我们将会根据信息披露规则进行披露，也请您理解","url":"https://stock-news.laohu8.com/highlight/detail?id=2439096268","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439096268?lang=zh_cn&edition=full","pubTime":"2024-05-31 19:03","pubTimestamp":1717153438,"startTime":"0","endTime":"0","summary":"产品业绩我们将会根据信息披露规则进行披露，也请您理解。故2023年度未进行利润分配。亿帆医药董秘：您好，截止2024年4月30日公司股东人数为40,217人。亿一生物与商业合作伙伴依据签署的合作协议各自承担义务与享有权利。后续销售情况如达到披露标准，公司将根据相关规则及时履行信息披露义务。2023年该产品销售额近五千万元，预计2024年将有进一步增长，具体该产品业绩公司将按相关法律法规对外披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024053100039403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0185","BK0077","BK0197","BK0239","BK0191","002019"],"gpt_icon":0},{"id":"2435034322","title":"亿帆医药最新公告：银杏叶丸获得新加坡注册批文","url":"https://stock-news.laohu8.com/highlight/detail?id=2435034322","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435034322?lang=zh_cn&edition=full","pubTime":"2024-05-13 20:40","pubTimestamp":1715604007,"startTime":"0","endTime":"0","summary":"亿帆医药公告，全资子公司SciGen Pte. Ltd于近日收到新加坡卫生科学局（Health Sciences Authority）核准签发的中成药注册批文，批准公司医保产品银杏叶丸在新加坡上市销售。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051300025071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","BK0185","002019","BK0191","BK0197","BK0077"],"gpt_icon":0},{"id":"2435222963","title":"亿帆医药(002019.SZ)：银杏叶丸获新加坡注册批文","url":"https://stock-news.laohu8.com/highlight/detail?id=2435222963","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435222963?lang=zh_cn&edition=full","pubTime":"2024-05-13 20:36","pubTimestamp":1715603773,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿帆医药(002019.SZ)公告，公司全资子公司SciGenPte.Ltd.(简称“赛臻公司”)于近日收到新加坡卫生科学局(简称“HSA”)核准签发的中成药注册批文，批准公司医保产品银杏叶丸在新加坡上市销售。该产品功能主治为：活血化瘀通络，增加心脑和肢体末梢的血流和供氧量。用于瘀血阻络引起的胸痹、心痛、肢体麻木等症。有助于改善成人认知功能和大脑记忆功能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1120733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0191","002019","BK0239","BK0197","BK0070","BK0077","BK0185"],"gpt_icon":0},{"id":"2433294912","title":"亿帆医药获首创证券增持评级，自有制剂、创新药进入放量周期，业绩反转趋势明确","url":"https://stock-news.laohu8.com/highlight/detail?id=2433294912","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433294912?lang=zh_cn&edition=full","pubTime":"2024-05-07 11:25","pubTimestamp":1715052336,"startTime":"0","endTime":"0","summary":"5月7日， 亿帆医药 获 首创证券 增持评级，近一个月亿帆医药获得10份研报关注。研报预计2024年至2026年公司营业收入分别为53.33亿元、63.62亿元和72.99亿元，同比增速分别为31.1%、19.3%和14.7%；归母净利润分别为5.07亿元、7.63亿元和10.31亿元。研报认为，由于公司新引进医药品种销售额的增加、医药自有产品销售额的大幅增加以及新增医药自研品种销售额的增加，使得公司的营业收入和净利润都有大幅增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050711381487dabf40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050711381487dabf40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","601136","002019"],"gpt_icon":0},{"id":"2433177680","title":"上海证券：给予亿帆医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2433177680","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433177680?lang=zh_cn&edition=full","pubTime":"2024-05-05 09:55","pubTimestamp":1714874117,"startTime":"0","endTime":"0","summary":"上海证券有限责任公司张林晚近期对亿帆医药进行研究并发布了研究报告《亿帆医药2023年报及2024年一季报点评：减值风险出清，自有产品显著增长，拐点已现》，本报告对亿帆医药给出买入评级，当前股价为13.24元。 亿帆医药 投资摘要 事件 2023年4月20日，公司发布2023年年报。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级7家；过去90天内机构目标均价为18.8。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050500000225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002019","161027"],"gpt_icon":0},{"id":"2431631805","title":"亿帆医药：感谢您的关注与提问。公司力争达到试生产条件同时预祝您五一劳动节快乐！","url":"https://stock-news.laohu8.com/highlight/detail?id=2431631805","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431631805?lang=zh_cn&edition=full","pubTime":"2024-04-30 18:06","pubTimestamp":1714471598,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药04月30日在投资者关系平台上答复投资者关心的问题。公司力争达到试生产条件。截止目前，已完成超过150例入组工作。如有实质性进展，公司将按相关法律法规及时公告。同时预祝您五一劳动节快乐！主要系子公司对母公司亿帆医药股份有限公司进行分红导致。亿帆医药董秘：您好，截止2024年4月19日公司股东人数为40,604人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000042637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK0077","BK0185","BK0191","002019","BK0197"],"gpt_icon":0},{"id":"2431457387","title":"天风证券：给予亿帆医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431457387","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431457387?lang=zh_cn&edition=full","pubTime":"2024-04-30 11:13","pubTimestamp":1714446820,"startTime":"0","endTime":"0","summary":"天风证券股份有限公司杨松,曹文清近期对亿帆医药进行研究并发布了研究报告《2023年业绩符合预期，2024Q1收入利润均加速增长》，本报告对亿帆医药给出买入评级，当前股价为13.16元。医药自有产品收入为24.3亿元，同比增长19.7%；医药其他产品收入为5.6亿元，同比下降19.5%；原料药收入为8.0亿元，同比增长1.6%，基本持平。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级5家；过去90天内机构目标均价为18.8。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000024149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002019","601162"],"gpt_icon":0},{"id":"2431858490","title":"华安证券：给予亿帆医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431858490","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431858490?lang=zh_cn&edition=full","pubTime":"2024-04-29 19:35","pubTimestamp":1714390526,"startTime":"0","endTime":"0","summary":"华安证券股份有限公司谭国超近期对亿帆医药进行研究并发布了研究报告《24Q1高增长初兑现，持续关注创新出海》，本报告对亿帆医药给出买入评级，当前股价为12.81元。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级5家；过去90天内机构目标均价为18.8。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900026847.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600909","002019"],"gpt_icon":0},{"id":"2430928954","title":"亿帆医药（002019）2024年一季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2430928954","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430928954?lang=zh_cn&edition=full","pubTime":"2024-04-25 06:10","pubTimestamp":1713996659,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期亿帆医药发布2024年一季报。根据财报显示，本报告期中亿帆医药营收净利润同比双双增长。截至本报告期末，公司营业总收入13.26亿元，同比上升41.28%，归母净利润1.46亿元，同比上升125.55%。其中，毛利率47.37%，同比减2.89%，净利率8.87%，同比增89.14%，销售费用、管理费用、财务费用总计4.22亿元，三费占营收比31.8%，同比减15.62%，每股净资产6.86元，同比减5.1%，每股经营性现金流0.15元，同比增8752.22%，每股收益0.12元，同比增126.18%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500011841.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002019"],"gpt_icon":0},{"id":"2429169747","title":"亿帆医药(002019.SZ)发一季度业绩，净利润1.46亿元，同比增长125.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429169747","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429169747?lang=zh_cn&edition=full","pubTime":"2024-04-23 17:49","pubTimestamp":1713865743,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿帆医药(002019.SZ)发布2024年第一季度报告，报告期内公司实现营业收入13.26亿元，同比增长41.28%;归属于上市公司股东的净利润1.46亿元，同比增长125.55%;归属于上市公司股东扣除非经常性损益净利润1.10亿元，同比增长83.93%;基本每股收益0.1201元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002019"],"gpt_icon":0},{"id":"2429150081","title":"4月23日亿帆医药涨5.81%，中银中国LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429150081","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429150081?lang=zh_cn&edition=full","pubTime":"2024-04-23 16:29","pubTimestamp":1713860966,"startTime":"0","endTime":"0","summary":"证券之星消息，4月23日亿帆医药涨5.81%，收盘报12.02元，换手率2.18%，成交量18.54万手，成交额2.21亿元。重仓亿帆医药的公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级4家。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为中银中国LOF。中银中国LOF目前规模为6.71亿元，最新净值0.7618，较上一交易日上涨0.17%，近一年下跌29.25%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300029857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0191","163801","BK0197","BK0077","002019","BK0185","BK0239"],"gpt_icon":0},{"id":"2429215072","title":"亿帆医药涨5.81%，华安证券二日前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2429215072","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429215072?lang=zh_cn&edition=full","pubTime":"2024-04-23 16:29","pubTimestamp":1713860958,"startTime":"0","endTime":"0","summary":"今日亿帆医药涨5.81%，收盘报12.02元。2024年4月21日，华安证券研究员谭国超发布了对亿帆医药的研报《轻装上阵迎接高速增长，创新全球化持续兑现》，该研报对亿帆医药给出“买入”评级。此外，太平洋研究员周豫,刘哲涵，西南证券研究员杜向阳近期也对该股发布了研报，同样给出“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为华安证券的谭国超。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300029851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600909","002019"],"gpt_icon":0},{"id":"2421347012","title":"亿帆医药(002019.SZ)控股子公司在研产品获欧盟委员会批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2421347012","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2421347012?lang=zh_cn&edition=full","pubTime":"2024-03-24 16:30","pubTimestamp":1711269000,"startTime":"0","endTime":"0","summary":"亿帆医药发布公告，该公司控股子公司 Evive Biotechnology Ireland Limited于北京时间2024年3月22日收到欧盟委员会签发的《委员会执行决议，COMMISSION IMPLEMENTING DECISION》，批准公司在研产品艾贝格司亭α注射液在欧盟上市销售，该决定基于欧洲药品管理局人用药品委员会的积极审查意见。本次 Ryzneuta上市许可申请获EC批准通过，公司将借助上述公司多年积累的广覆盖的销售渠道和客户资源，快速打开Ryzneuta在欧盟的市场，提高Ryzneuta在全球市场的影响力和市占率，助推该产品惠及全球更多CIN患者。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-24/doc-inapmkct0922927.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-24/doc-inapmkct0922927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0070","BK0239","BK0185","002019","BK0191","BK0197","BK0077"],"gpt_icon":0},{"id":"2415204543","title":"亿帆医药(002019.SZ)：麻芩消咳颗粒获得新加坡注册批文","url":"https://stock-news.laohu8.com/highlight/detail?id=2415204543","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2415204543?lang=zh_cn&edition=full","pubTime":"2024-02-29 19:52","pubTimestamp":1709207520,"startTime":"0","endTime":"0","summary":"亿帆医药发布公告，公司全资子公司SciGen Pte.Ltd.于近日收到新加坡卫生科学局核准签发的中成药注册批文，批准公司独家医保产品麻芩消咳颗粒在新加坡上市销售。本次麻芩消咳颗粒获新加坡注册批文，是公司继独家产品复方银花解毒颗粒后的第二个中药核心产品成功实现海外注册，为公司中药产品海外注册积累了宝贵经验，进一步丰富了公司境外产品结构与产品管线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-29/doc-inaktftc1234432.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-29/doc-inaktftc1234432.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0070","002019","SG9999016042.SGD","FSTM.SI","BK0197","BK6523","BK0185","BK0191","LU0898667661.SGD","STI.SI","SG9999000343.SGD","LU0205439572.USD","SG9999001135.SGD","SG9999004360.SGD","BK0077","LU0831103253.SGD","BK6516","FSTAS.SI","S68.SI","ES3.SI","BK0239","BK6033"],"gpt_icon":0},{"id":"2412968374","title":"亿帆医药(002019.SZ)部分董事、高管等完成增持301.34万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2412968374","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2412968374?lang=zh_cn&edition=full","pubTime":"2024-02-18 16:12","pubTimestamp":1708243920,"startTime":"0","endTime":"0","summary":"亿帆医药(002019.SZ)公告，截至2024年2月8日，公司部分董事、高级管理人员及核心人员共计220人以集中竞价方式共计增持公司股份301.34万股，占目前公司总股本的0.25%，增持金额3062.66万元，本次增持计划实施完成。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-18/doc-inaimwwq3269988.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-18/doc-inaimwwq3269988.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0070","BK0185","BK0077","BK0197","BK0239","BK0191","002019"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2004-07-13","address":"浙江省杭州市临安区临安经济开发区","stockEarnings":[{"period":"1week","weight":-0.0038},{"period":"1month","weight":-0.0663},{"period":"3month","weight":0.072},{"period":"6month","weight":-0.1474},{"period":"1year","weight":-0.1302},{"period":"ytd","weight":-0.1231}],"companyName":"亿帆医药股份有限公司","boardCode":"AI0027","perCapita":"138754股","boardName":"医药制造业","registeredCapital":"122602万元","compareEarnings":[{"period":"1week","weight":-0.0116},{"period":"1month","weight":-0.0438},{"period":"3month","weight":-0.0153},{"period":"6month","weight":0.0392},{"period":"1year","weight":-0.0786},{"period":"ytd","weight":0.0138}],"survey":" 亿帆医药股份有限公司主要从事医药产品、原料药和高分子材料的研发、生产、销售及药品推广服务。主导产品为中成药、化药、生物药、维生素B5、维生素原B5等。","serverTime":1718648923341,"listedPrice":12.57,"stockholders":"39855人(较上一季度减少1.77%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.23.1","shortVersion":"4.23.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亿帆医药(002019)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亿帆医药(002019)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亿帆医药,002019,亿帆医药股票,亿帆医药股票老虎,亿帆医药股票老虎国际,亿帆医药行情,亿帆医药股票行情,亿帆医药股价,亿帆医药股市,亿帆医药股票价格,亿帆医药股票交易,亿帆医药股票购买,亿帆医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亿帆医药(002019)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亿帆医药(002019)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}